The medication is generally applied across therapeutic domains involving acute or chronic physical discomfort in felines. Metacam Katzen is used to help manage symptom clusters related to inflammatory or irritative states. It is relevant for the supportive management of symptoms linked to chronic conditions like osteoarthritis in older cats, as well as for short-term support during acute episodes, including post-operative recovery following surgical procedures.

This medication helps address symptoms that create noticeable physiological strain, such as lameness, stiffness, and impaired mobility. This approach generally assists with improving day-to-day comfort during symptomatic periods, which supports the patient during difficult episodes by easing distress. It is commonly used for symptoms that interfere with daily functioning, such as difficulty jumping or reluctance to move.

Quick Fact: Symptomatic Support

Who Can and Cannot Use Metacam Katzen?

The eligibility profile for Metacam Katzen defines strict criteria for use, as established by regulatory authorities. The medicine is authorized only for the feline species and is restricted to cats 6 weeks of age or older and weighing at least 2 kg.

Absolute Contraindications

Use is strictly prohibited in the following populations:

• Cats with known hypersensitivity to Meloxicam or its excipients.
• Animals suffering from gastrointestinal disorders (e.g., haemorrhage or ulcerogenic lesions) or pre-existing haemorrhagic disorders.
• Cats with severely impaired hepatic, renal, or cardiac function.
• Pregnant or lactating animals (queens), as regulatory safety has not been established.
• Cats concurrently receiving other NSAIDs or glucocorticosteroids.

Conditional Use Restrictions

Regulatory documents advise special caution or avoidance in specific physiologic states:

• Use should be avoided in dehydrated, hypovolaemic, or hypotensive animals due to the potential risk of renal toxicity.
• The use in debilitated aged animals may involve additional risk and requires careful management.

Interactions with other medicines and products

Official regulatory documents define specific substances and conditions that introduce a risk of significant interaction, primarily related to additive toxicity and altered drug exposure.

Interaction-Related Restrictions

Pharmacodynamic and Exposure Interactions

Regulatory information notes that co-administration with other potentially nephrotoxic drugs or diuretics should be avoided, particularly in vulnerable animals, due to an increased potential for renal toxicity. Furthermore, substances with high plasma protein binding may compete with the active ingredient, Meloxicam, leading to an increase in the free plasma concentration of one or both agents, which may result in toxic effects.

Timing and Population-Specific Rules

When switching from prior treatment with other anti-inflammatory substances, a treatment-free period of at least 24 hours must be observed before commencing Metacam Katzen. This timing-based requirement helps manage the risk of additive toxicity. The risk of interaction with nephrotoxic drugs is officially stated to be heightened in animals that are dehydrated, hypovolemic, or hypotensive.

The mechanism of Metacam Katzen is rooted in the targeted suppression of specific signaling molecules, resulting in the physiological modulation of active signaling. The drug's primary action involves its role as a preferential inhibitor of the enzyme Cyclooxygenase-2 (COX-2). By binding reversibly to the enzyme's active site, the drug interrupts the Arachidonic Acid Cascade, a molecular step that halts the production of pro-inflammatory signaling molecules called prostaglandins. This molecular consequence drives the modulation of peripheral inflammatory signaling. Reduced prostaglandin synthesis decreases localized vascular permeability and fluid extravasation at sites of tissue changes. Crucially, the diminished chemical environment lowers the excitability of peripheral nociceptors (pain receptors), thereby reducing the propagation of afferent signaling and contributing to the alteration of signal dynamics within targeted pathways.

Metacam Katzen is a veterinary medicine formulated as a 0.5 mg/ml oral suspension containing meloxicam, intended for administration via the mouth. The product is designed to be given either mixed with food or delivered directly into the cat's mouth. Accurate dosing is a critical procedural requirement. The suspension must be shaken well before use, and the cat's body weight must be determined as precisely as possible to ensure the correct volume is calculated and administered using the calibrated dosing device.

Official Labeled Dosing Regimens

Standard maintenance and follow-up therapy, regardless of the initial regimen, is standardized to 0.05 mg/kg BW, administered once daily to maintain a 24-hour interval between doses. There are defined limits for the total duration of use. For chronic treatment, if no clinical improvement is observed, the treatment course is discontinued after 14 days. For oral follow-up to post-operative pain management, the duration is limited to a maximum of four days. Furthermore, the product is restricted to use in cats that are 6 weeks of age or older.

Research evidence / Overview of studies for Metacam Katzen

Evidence for Short-Term Pain and Inflammation

Research has examined the use of this medicine in the context of short-term outcomes related to physical discomfort following surgical procedures. These studies were evaluated in felines undergoing common operations. The research design involved short-term randomized controlled trials (RCTs) that compared the medicine against other commonly used pain relievers. Studies monitored outcomes such as a cat's level of pain and recovery status. Some comparative research described patterns where the number of cats requiring supplementary pain medication was different from control groups. The research duration is short, and limited information is available regarding recovery long after the administration has ended.

Evidence for Chronic Musculoskeletal Pain

The primary research for chronic joint discomfort, such as osteoarthritis, was evaluated in long-term clinical studies. These studies explored the effects of administration over several months, often relying on prospective designs and observational settings evaluating daily-life functioning in older felines. Research highlights changes measured during the study period using patient-reported outcomes describing perceived discomfort and overall quality of life. High proportions of owners participating in these long-term studies frequently provided positive-scale ratings on their cat's mobility and demeanor. A key limitation is the heavy reliance on subjective assessment by pet owners and the fact that the full range of long-term effects are not fully established across all populations.

Research in Specific Feline Populations

Research has also specifically examined the use of this medicine in aged cats with co-existing degenerative joint discomfort (DJD) and stable chronic kidney disease (CKD). These studies were evaluated in smaller trials and retrospective comparisons. Studies reported patterns where renal excretory function markers was not observed in the measured markers when compared to control groups. Retrospective analyses described survival times that aligned with previously published survival times for cats with CKD. However, one prospective trial reported a statistically greater mean measurement of urine protein levels (UPC ratio) in the studied group, a finding that contributes to the broader evidence landscape on monitoring.

Key Studies & References

1. Metacam 0.5 mg/ml - Oral suspension (cats, guinea pigs) - EU Regulatory Status

Common questions about Metacam Katzen (FAQ)

Q: Is Metacam Katzen the same as Metacam for dogs?

According to official regulatory documents, the cat oral suspension is formulated to a different, lower concentration (0.5 mg/ml) of the active ingredient, meloxicam. This cat-specific product is distinct from the concentration typically found in the dog oral suspension. Use of the higher-concentration dog product is generally restricted for use in cats.

Q: How long after starting Metacam Katzen might a cat's owner typically notice a change?

Official product information for chronic musculo-skeletal disorders indicates that a clinical response is normally observed within 7 days of starting treatment. If there is no apparent improvement in the animal’s condition after 14 days, the product label indicates that the treatment course should be stopped.

Q: What is the expected duration of action for a single use of Metacam Katzen?

Regulatory information indicates that the drug is eliminated with a half-life of approximately 24 hours in cats. The administration schedule is based on a 24-hour interval between doses.

Q: What makes Metacam Katzen distinct from other meloxicam products?

Metacam Katzen is specifically formulated as a low-concentration 0.5 mg/ml oral suspension that may contain excipients, such as flavorings, appropriate for feline administration. This formulation is designed to allow for accurate dosing in cats, and is distinct from the higher concentration meloxicam products used for other animals.

Q: Is Metacam Katzen typically given daily or only when needed for pain?

The official dosage schedule suggests a single initial dose followed by a once-daily maintenance dose for the duration of the prescribed treatment course, which is consistent with structured, non-as-needed use.

Q: What is the main concern described in official warnings regarding kidney function and this drug?

Official warnings state that the drug is contraindicated in cats suffering from impaired renal function (kidney disease). Furthermore, inappropriate use has been associated with reports of serious adverse outcomes, including acute renal failure.

Q: What kind of research has been done on the long-term use of Metacam Katzen?

The official indication, or approved use, for this drug includes the alleviation of pain and inflammation in chronic musculo-skeletal disorders. This indication is granted based on supporting safety and efficacy research for long-term use under veterinary supervision.

Q: What are the most serious possible side effects to be aware of when using this medicine?

The official documentation describes several severe adverse reactions that have been reported, including renal failure, gastrointestinal ulceration, internal bleeding, and elevated liver enzymes. Official instructions emphasize that treatment should be immediately discontinued if any adverse reactions are observed.

Q: Is it necessary to avoid certain types of food or supplements while a cat is using Metacam Katzen?

Official documentation contraindicates concurrent use with other non-steroidal anti-inflammatory drugs (NSAIDs) and glucocorticosteroids (steroids). Users are also advised to avoid concurrent use of other potentially nephrotoxic drugs, which are substances that can affect kidney function.

Q: Are there any specific safety warnings for older or senior cats using Metacam Katzen?

Yes. Regulatory cautions state that the use of the drug in debilitated aged animals may involve additional risk. If the drug is used in these animals, clinical management may require a reduced dosage and extra care.

Q: Can cats with kidney problems use Metacam Katzen?

The product information states that Metacam Katzen is formally contraindicated, meaning it should not be used, in cats suffering from impaired renal function (kidney disease).

Q: Is there any research evidence related to the use of Metacam Katzen in very young cats?

The official product information defines an age restriction and states that the product is contraindicated for use in cats less than 6 weeks of age. This indicates that safety for use in very young cats below that age has not been established for this product.

Q: Can Metacam Katzen be used for cats with liver disease?

The official product information states that Metacam Katzen is formally contraindicated, meaning it should not be used, in cats suffering from impaired hepatic function (liver disease).

Q: What are the official recommendations for stopping the use of Metacam Katzen?

The product documentation indicates that treatment should be stopped after 14 days at the latest if no clinical improvement is apparent. Additionally, if any adverse reactions are observed during use, treatment should be immediately discontinued.

Q: Does Metacam Katzen affect the cat's appetite?

Loss of appetite (anorexia) is listed among the typical adverse reactions reported in the official product literature for this class of drug.

Q: Are there specific laboratory tests recommended while a cat is on long-term Metacam Katzen?

Due to contraindications related to kidney and liver function, regulatory precautions advise that animals should undergo a thorough examination before use. Ongoing clinical monitoring for adverse reactions is generally recommended while the cat is on long-term treatment.

Q: Are there different restrictions for short-term versus long-term use of Metacam Katzen?

Yes, regulatory documents define different rules for these two contexts. This includes different initial dosing requirements and different maximum treatment durations defined for short-term use (such as post-operative pain) versus chronic (long-term) use.

Q: What are the symptoms described in the official literature for an accidental overdose?

In case of overdosing, the official literature states that gastrointestinal, renal (kidney), and hepatic (liver) toxicity may occur. Reported signs include vomiting, diarrhea, lethargy, increased drinking, and other signs of kidney and liver toxicity.

Q: What is the active ingredient in Metacam Katzen?

The active ingredient in Metacam Katzen oral suspension is meloxicam. Meloxicam belongs to a class of medications known as non-steroidal anti-inflammatory drugs (NSAIDs).

Q: Is it normal for a cat to seem slightly sedated after using Metacam Katzen?

Lethargy and depression are noted in the official adverse reactions. These effects are documented and should be discussed with the prescribing professional if concerns arise.

Q: Are there known interactions with common medications like diuretics?

Official regulatory warnings state that concurrent administration with diuretics (medications that increase urination) should be avoided. This is due to the potential for an increased risk of renal toxicity (kidney damage), particularly in animals that are dehydrated.

How to Store and Dispose of Metacam Katzen?

Official regulatory documents define strict rules for the storage and disposal of Metacam 0.5 mg/ml oral suspension for cats.

Storage Requirements

The unopened product does not require any special storage conditions, but must always be stored out of the sight and reach of children. The closure is designed to be child-resistant.

Disposal Instructions

Unused or expired product must be disposed of in accordance with local requirements. It is officially prohibited to dispose of the product via wastewater (sinks or toilets), and users are directed to utilize pharmaceutical take-back schemes.